Viewing nowCombinationGlucytapomin Extended Release Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.

MFDS item code 202300606 · Approved 2023.02.17 · Insurance code 693202540
Improvement of glycemic control in patients with type 2 diabetes
This medication assists in improving blood sugar control in patients with type 2 diabetes in conjunction with dietary management and exercise. It helps to effectively manage blood sugar through the combination of sitagliptin and metformin. Patients can greatly benefit from taking this medication alongside consistent dietary control and regular exercise. This medication is used in the treatment of type 2 diabetes.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To preserve its extended-release properties, this medicine must be swallowed whole; do not split, crush, grind, or chew it. Cases have been reported in which the medicine was not completely dissolved and was excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients unable to achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg. The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because of its metformin component (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains both sitagliptin and metformin and is primarily used for the treatment of type 2 diabetes. First, an allergic reaction may occur when taking this medication, so if symptoms such as skin rash, itching, or difficulty breathing occur, discontinue use immediately and consult a physician. Additionally, serious inflammation of the pancreas, known as pancreatitis, may develop; thus, if abdominal pain, vomiting, or severe stomach pain occurs, inform medical personnel immediately. This medication should not be given to patients with significantly reduced kidney function, severe infections or dehydration, or acute myocardial infarction. Particularly, administration of this medication should be temporarily halted before and after tests using iodine contrast agents, and it should be resumed only after kidney function has recovered. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. While on this medication, there is a risk of hypoglycemia, so care should be taken when skipping meals or engaging in vigorous exercise; co-administration with other blood glucose-lowering agents may lead to easier onset of hypoglycemic symptoms. Patients with poor liver function should also be cautious when using this medication, and it is advisable to avoid use in cases of liver function abnormalities. Regular checks of kidney function and blood tests, including vitamin B12 levels, should be conducted while on this medication. Excessive alcohol consumption can increase the risk of a serious side effect known as lactic acidosis, so it is safest to avoid drinking. If surgery is necessary, this medication should be discontinued 48 hours prior to the procedure, and it can be resumed only after normal kidney function is confirmed post-surgery. Furthermore, this medication may cause severe joint pain or skin conditions in some patients, so inform a physician if these symptoms develop. Finally, this medication has not been established as safe and effective for children, so it should not be used by individuals under 18 years of age.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to keep it at room temperature between 1 and 30 degrees Celsius.
Pale blue, double convex, oval-shaped extended release film-coated tablets
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.